NCT00510627View on ClinicalTrials.gov

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2007

Study Completion Date

December 31, 2010

Conditions
Metastatic Liver CancerSecondary Liver CancerLiver Neoplasm
Interventions
DEVICE

Radiofrequency Ablation (RFA)

The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.

DRUG

Chemotherapy

Standard of care chemotherapy regimen

Trial Locations (2)

10016

New York University, New York

44195

The Cleveland Clinic Foundation, Cleveland

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT00510627 - Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases | Biotech Hunter | Biotech Hunter